1991 (+12 months); 2 months later, he developed skin GVHD reactivation (mild) and oral CsA (6 mg/kg) and methylprednisolone (1 mg/kg) were reintroduced. In Febru-A case of Kaposi's sarcoma (KS) in an allogenic BMT recipient is reported. A 26-year-old man underwent ary 1992 (+19 months) no clinical evidence of chronic GVHD was detectable and the patient started tapering his allogeneic bone marrow transplantation for microdrepanocytosis. He received prolonged immunosuppressive immunosuppressive treatment. In April 1992 (+21 months) he presented with edema of the left leg and scanty reddish therapy for mild chronic GVHD. Two years after BMT he developed KS localized to the skin. The KS improved blue maculas, interpreted as ecchymosis. The edema of the left foot improved with time but bilateral perimalleolar nodrapidly and outcome was complete remission after cessation of immunosuppression.
1
were occasionally observed; scattered hemosiderin granules More recently, a case of KS in a patient after autologous were also present free or inside macrophages (Figures 1 and bone marrow transplantation has been reported. 2 Here we 2). Computed tomography examination of chest and abdoreport a case of KS occurring after allogeneic BMT.
men did not reveal any internal visceral or nodal involvement. The patient continued to reduce the immunosuppressive therapy, stopping 6 months later. After cessation of Case report immunosuppressive treatment the lesions regressed within 8 months. A skin biopsy performed in February 1994 (+43 A 26-year-old patient (Table 1) was transplanted for months) showed residual chronic GVHD with complete microdrepanocytosis from an HLA-identical sibling in July disappearance of the proliferating vessels; the dermis was 1990. He had been regularly transfused since the age of 14.
involved by collagenation with presence of scattered lymConditioning included busulfan given orally at a dose of phocytes and frequent hemosiderin granules. The biopsy 14 mg/kg for 4 consecutive days, cyclophosphamide given specimens were not studied for presence of human herpes i.v at a dose of 120 mg/kg for 2 consecutive days and antivirus as DNA analysis on tissue samples by PCR was not lymphocyte globulin from day −5 to +5.
3 He received CsA available. Lymphocyte subpopulations were examined four and 'short' methotrexate (up to day +6) for prevention of GVHD. Complete donor engraftment was documented on day +39 by hemoglobin chain synthesis and cytogenetic of CMV infection before or after BMT or at the onset of KS; human immune deficiency virus HIV-1 and HIV-2 titers were negative before and after diagnosis. The patient is currently in complete remission for KS and cured from his congenital disease without signs of chronic GVHD at Ͼ60 months from BMT.
Discussion
Kaposi's sarcoma (KS) was first described by Moritz Kaposi in 1872 as 'idiopathic, multiple, pigmented sarcomas of the skin'. It was recognized as an unusual tumor primarily affecting elderly males of Mediterranean or Ashkenazic Jewish origin. 4 This form, called 'classic' or European, has an indolent clinical course with rare nodal involvement and extracutaneous localization. The endemic form of KS was recognized in Central Africa with an incidence of 15% of all tumors and with a wide spectrum of clinical severity. 5 The epidemic form of KS that occurs in association with AIDS was recognized two decades ago among male homosexuals in the USA. 6 In the last few years the tumor has also been frequently diagnosed in patients with impaired immunologic function after an organ transplant. 1 Porta et al 2 reported a case of KS after an autologous bone marrow transplant. One of the long-term complications of organ or bone marrow transplant is the development of secondary tumors. 7 The intensive chemotherapy during preparation for transplant, use of irradiation-based conditioning therapy and the severe immunosuppression after transplant may play a role in the development of second neoplasms. 7, 8 Disturbance of immunity does not include only depression of immunity, but impaired immunostimulation and chronic antigenic stimulation can lead to that may activate neoplasm formation. 1, 10 Recently, a new human herpes virus has been suggested as the cause of AIDS-associated Kaposi's sarcoma. 11 The neoplasm has a times between the 32nd and 52nd months of follow-up different clinical course in each form, but the behavior of ( Table 2) . A persistent abnormal CD4/CD8 ratio with an this tumor in patients with compromised immunity due to increased absolute number of CD8 lymphocytes and altered immunosuppressive therapy because of organ and bone CD16 count were observed without significant modifimarrow transplant is characteristic; in fact the tumor usucations during and after immunosuppression tapering ally dramatically regresses upon withdrawal or reduction of ( Table 2 ). In view of the suggested role of CMV infection immunosuppressive therapy. 12 in the etiology of KS, virologic examinations were repeatThe patient reported here has received prolonged and edly performed, with no detection of the virus in blood, severe immunosuppressive treatment for GVHD. The neosputum and urine. The patient did not suffer a reactivation plasm arose 29 months after BMT, during the tapering of immunosuppression and was confined to the skin of the lower limbs. With the aim of preventing reactivation of Table 2 Lymphocyte subpopulation of patient GVHD, the immunosuppressive therapy was tapered gradually and complete cessation required a period of 6 months. apy in solid organ transplant recipients usually leads to
